Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure
出版年份 2013 全文链接
标题
Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure
作者
关键词
-
出版物
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume 69, Issue 2, Pages 451-462
出版商
Oxford University Press (OUP)
发表日期
2013-09-04
DOI
10.1093/jac/dkt347
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Evaluation of the effect of oritavancin on Clostridium difficile spore germination, outgrowth and recovery
- (2013) C. H. Chilton et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Both Fidaxomicin and Vancomycin Inhibit Outgrowth of Clostridium difficile Spores
- (2012) Charlotte A. Allen et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI
- (2012) T. J. Louie et al. CLINICAL INFECTIOUS DISEASES
- Relapse Versus Reinfection: Recurrent Clostridium difficile Infection Following Treatment With Fidaxomicin or Vancomycin
- (2012) I. Figueroa et al. CLINICAL INFECTIOUS DISEASES
- Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials
- (2012) Derrick W. Crook et al. CLINICAL INFECTIOUS DISEASES
- Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin
- (2012) O. A. Cornely et al. CLINICAL INFECTIOUS DISEASES
- Effectiveness of a short (4 day) course of oritavancin in the treatment of simulated Clostridium difficile infection using a human gut model
- (2012) C. H. Chilton et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection
- (2012) G. S. Crowther et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection
- (2012) P.N. Wiegand et al. JOURNAL OF HOSPITAL INFECTION
- Progress with a difficult infection
- (2012) Mark H Wilcox LANCET INFECTIOUS DISEASES
- Postantibiotic Effect of Fidaxomicin and Its Major Metabolite, OP-1118, against Clostridium difficile
- (2011) Farah Babakhani et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Fidaxomicin versus Vancomycin forClostridium difficileInfection
- (2011) Thomas J. Louie et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Changing Epidemiology of Clostridium difficile Infections
- (2010) J. Freeman et al. CLINICAL MICROBIOLOGY REVIEWS
- Economic healthcare costs of Clostridium difficile infection: a systematic review
- (2010) S.S. Ghantoji et al. JOURNAL OF HOSPITAL INFECTION
- A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin
- (2010) G. W. Tannock et al. MICROBIOLOGY-SGM
- Recurrent Clostridium difficile infection: A review of risk factors, treatments, and outcomes
- (2009) Stuart Johnson JOURNAL OF INFECTION
- Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model
- (2008) S. D. Baines et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model
- (2008) S. D. Baines et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started